Difference between revisions of "Porfimer (Photofrin)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or" to "or") |
||
| (10 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Photosensitizing agent used in photodynamic therapy (PDT), comprised of a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units. Light from photodynamic therapy excites porphyrin and results in the propagation of radical reactions, including the formation of superoxide and hydroxyl radicals. Ischemic necrosis due to vascular occlusion thought to be mediated by thromboxane A2 (TXA2) release and has also been observed.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020451s020lbl.pdf Porfimer (Photofrin) package insert]</ref><ref>[ | + | Class/mechanism: Photosensitizing agent used in photodynamic therapy (PDT), comprised of a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units. Light from photodynamic therapy excites porphyrin and results in the propagation of radical reactions, including the formation of superoxide and hydroxyl radicals. Ischemic necrosis due to vascular occlusion thought to be mediated by thromboxane A2 (TXA2) release and has also been observed.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020451s020lbl.pdf Porfimer (Photofrin) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/porfimer.pdf Porfimer (Photofrin) package insert (locally hosted backup)]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
*[http://www.uptodate.com/contents/porfimer-patient-drug-information Porfimer (Photofrin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/porfimer-patient-drug-information Porfimer (Photofrin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/porfimer-patient-drug-information Porfimer (Photofrin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/porfimer-patient-drug-information Porfimer (Photofrin) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *1993-04-19: EURD | ||
| + | ==Also known as== | ||
| + | *'''Brand name:''' Photofrin | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
| − | [[Category: | + | [[Category:Intravenous medications]] |
| + | [[Category:Photosensitizers]] | ||
| + | [[Category:FDA approved in 1995]] | ||
| + | [[Category:EMA approved in 1993]] | ||
Latest revision as of 00:06, 6 July 2024
General information
Class/mechanism: Photosensitizing agent used in photodynamic therapy (PDT), comprised of a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units. Light from photodynamic therapy excites porphyrin and results in the propagation of radical reactions, including the formation of superoxide and hydroxyl radicals. Ischemic necrosis due to vascular occlusion thought to be mediated by thromboxane A2 (TXA2) release and has also been observed.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.[1]
Patient drug information
History of changes in EMA indication
- 1993-04-19: EURD
Also known as
- Brand name: Photofrin